Aytu BioPharma Inc. (NASDAQ:AYTU) Given Average Rating of “Hold” by Brokerages

Aytu BioPharma Inc. (NASDAQ:AYTU) has earned a consensus recommendation of “Hold” from the five research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.3333.

A number of equities research analysts recently weighed in on AYTU shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Wednesday, April 8th. Wall Street Zen raised shares of Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th. Finally, Zacks Research cut shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 31st.

Aytu BioPharma Stock Performance

Shares of NASDAQ:AYTU opened at $2.50 on Friday. The firm has a 50 day moving average of $2.59 and a 200 day moving average of $2.44. The company has a quick ratio of 1.03, a current ratio of 1.16 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $26.83 million, a price-to-earnings ratio of -0.65 and a beta of 0.28. Aytu BioPharma has a 52 week low of $1.22 and a 52 week high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.79). The company had revenue of $15.17 million during the quarter, compared to analysts’ expectations of $12.17 million. Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. On average, sell-side analysts predict that Aytu BioPharma will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aytu BioPharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Daytona Street Capital LLC purchased a new stake in shares of Aytu BioPharma during the 4th quarter valued at $26,000. Rothschild Wealth LLC purchased a new position in Aytu BioPharma during the 4th quarter worth $52,000. Dimensional Fund Advisors LP purchased a new position in Aytu BioPharma during the 3rd quarter worth $58,000. Bellevue Asset Management LLC acquired a new position in Aytu BioPharma during the 4th quarter valued at about $65,000. Finally, XTX Topco Ltd purchased a new stake in Aytu BioPharma in the fourth quarter valued at about $67,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.